SMG8

Across TCGA pan-cancer cohorts, SMG8 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SMG8 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SMG8 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SMG8 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, CCRCC, and HNSC are the cancer types where SMG8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.410	0.721	<.001	48	view →
CCRCC	OS	Quartile	All	0.683	0.950	.004	21	view →
HNSC	OS	Quartile	All	0.543	0.795	.008	9	view →
LUAD	DFS	Median	All	0.964	0.871	.022	9	view →
OV	DFS	Tertile	All	0.612	0.884	.026	4	view →
LSCC	OS	Tertile	All	0.738	1.000	.034	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SMG8–PDAC (OS)

Open the PDAC breakdown →